奥希替尼对表皮生长因子受体（EGFR）第20外显子插入阳性肺腺癌的疗效 - Suppr

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

作者信息

Piotrowska Zofia, Fintelmann Florian J, Sequist Lecia V, Jahagirdar Balkrishna

机构信息

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

J Thorac Oncol. 2018 Oct;13(10):e204-e206. doi: 10.1016/j.jtho.2018.05.017.

DOI:10.1016/j.jtho.2018.05.017

PMID:30244855

Abstract

摘要

相似文献

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

J Thorac Oncol. 2018 Oct;13(10):e204-e206. doi: 10.1016/j.jtho.2018.05.017.

Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.

J Thorac Oncol. 2019 Jul;14(7):e151-e153. doi: 10.1016/j.jtho.2019.02.034.

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.

Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.

Cancer Genet. 2021 Aug;256-257:57-61. doi: 10.1016/j.cancergen.2021.04.001. Epub 2021 Apr 10.

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.

Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.

Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

Lung Cancer. 2020 Mar;141:9-13. doi: 10.1016/j.lungcan.2019.12.013. Epub 2019 Dec 20.

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response .

Cancer Discov. 2021 Jul;11(7):1736-1753. doi: 10.1158/2159-8290.CD-20-1385. Epub 2021 Mar 11.

Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.

Clin Lung Cancer. 2020 Sep;21(5):e493-e496. doi: 10.1016/j.cllc.2020.04.010. Epub 2020 Apr 15.

EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.

Thorac Cancer. 2021 May;12(9):1441-1444. doi: 10.1111/1759-7714.13920. Epub 2021 Mar 7.

引用本文的文献

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover.

Cell Death Discov. 2024 Oct 28;10(1):454. doi: 10.1038/s41420-024-02220-y.

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation.

Front Oncol. 2024 Jun 11;14:1367204. doi: 10.3389/fonc.2024.1367204. eCollection 2024.

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.

JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan.

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?

Lung Cancer (Auckl). 2022 Oct 25;13:67-73. doi: 10.2147/LCTT.S385437. eCollection 2022.

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with exon 20 insertion mutations.

Front Oncol. 2022 Sep 2;12:949304. doi: 10.3389/fonc.2022.949304. eCollection 2022.

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations.

Med Chem Res. 2022;31(10):1647-1662. doi: 10.1007/s00044-022-02952-5. Epub 2022 Sep 1.

The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.

Curr Oncol. 2022 Apr 11;29(4):2630-2643. doi: 10.3390/curroncol29040215.

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.

Oncologist. 2022 Feb 3;27(1):7-12. doi: 10.1093/oncolo/oyab002.

Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.

Expert Rev Anticancer Ther. 2022 Jan;22(1):3-16. doi: 10.1080/14737140.2022.2016397. Epub 2021 Dec 28.

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors.

Cancers (Basel). 2021 Dec 2;13(23):6081. doi: 10.3390/cancers13236081.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献